Reprogrammed Stem Cells Are Rife with Mutations
By Emily Singer,
Technology Review
| 03. 03. 2011
The findings cast doubt on a promising alternative to the use of embryonic stem cells in medicine.
Adult cells that have been reprogrammed into stem cells harbor a number of genetic mutations, some of which appear in genes that have been linked to cancer. While scientists don't yet know how this might affect the use of the cells in medicine, they say the findings show that the cells need to be studied much more extensively.
"As we think about using [these] cells for therapy, we will want to consider what kinds of screening tests we want to do," says Lawrence Goldstein, a professor of molecular biology at the University of California, San Diego. One of the major concerns about stem-cell-based therapies has been whether they carry a risk of cancer; both stem cells and cancer cells are distinguished by their ability to continually divide.
In two studies published today in Nature, researchers analyzed the genome of induced pluripotent stem (iPS) cells, adult cells that have been genetically or chemically reverted to the stem cell state. These cells have attracted intense interest from both scientists and the public as a potential alternative to embryonic stem cells. Like...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...